Opinion|Videos|December 2, 2024
Malignancy Risks of Neurokinin Receptor Antagonists
Panelists discuss clinical trial data suggesting a small but higher incidence of endometrial hyperplasia or malignancy with fezolinetant, while no cases of endometrial hyperplasia or malignancy were observed with elinzanetant in a long-term safety study.
Advertisement
Episodes in this series
What does data from the clinical trials suggest about the incidence of neoplasms with fezolinetant and elinzanetant?
Notes:Across 3 clinical trials, fezolinetant is associated with a small, but higher incidence of endometrial hyperplasia or endometrial malignancy.
There were no cases of endometrial hyperplasia or endometrial malignancy observed with elinzanetant in a long-term safety study.
Advertisement
Related to this article
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
Hugh Taylor, MD, explains that imaging in endometriosis is best for ruling out other causes of pelvic pain and cannot exclude the diagnosis.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
The FDA office of Women's Health and Center for Drug Evaluation and Research and hosting a public workshop with a focus on testosterone use in menopausal women.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, weighs his own experience with pellet therapy against guideline evidence, then he and Maria Uloko, MD, close with candid advice for clinicians too afraid of hormones to start prescribing.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, walk through real-world dosing, cost workarounds, and the labs that actually matter for safety and efficacy.
Bruce Dorr, MD, FACOG, URPS, FMCP-M, and Maria Uloko, MD, reframe testosterone candidacy around clinical presentation and hormone state, not age cutoffs or a single number on a chart.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Earlier menopause associated with less favorable functional, structural neurological outcomes
2
FDA holding public meeting on testosterone use in menopausal women
3
Off-label testosterone dosing, access, and lab monitoring in the US
4
Pellet therapy and practical advice for hesitant prescribers
5